# A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD)

> **NCT00216489** · PHASE4 · COMPLETED · sponsor: **Janssen Cilag Pharmaceutica S.A.C.I., Greece** · enrollment: 191 (actual)

## Conditions studied

- Gastroesophageal Reflux
- Heartburn

## Interventions

- **DRUG:** rabeprazole sodium

## Key facts

- **NCT ID:** NCT00216489
- **Lead sponsor:** Janssen Cilag Pharmaceutica S.A.C.I., Greece
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** —
- **Final completion:** 2005-11
- **Target enrollment:** 191 (ACTUAL)
- **Last updated:** 2010-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00216489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00216489, "A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00216489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*